Debt Is Available, But Each Company Is Getting A Different Kind Of Capital
Mega Or received large institutional demand for two bond-series expansions, Opal Balance extended a binding bank facility, and Phoenix received a stable BBB international rating. The April 24 filings point to accessible capital, but also to a clear hierarchy of funding quality and remaining conditions.
MEGA OR, OPAL BALANCE, and PHOENIX published three credit-related filings on April 24, but not the same kind of credit story. MEGA OR is testing the bond market through an institutional tender for two series expansions. OPAL BALANCE is renewing a short bank source for check discounting. PHOENIX is receiving an international rating that validates holding-company liquidity and subsidiary dividends.
Money is still available when lenders can underwrite a clear asset, loan book, or holding-company cash source. Bargaining power, however, is not distributed equally: one company receives an international rating for a structure that already generates cash, one receives another year of bank access, and one receives strong institutional demand that still needs to become an actual issuance.
The same debt market is ranking companies by source quality
The comparison sharpens the current credit hierarchy. Size is only one part of the story. The source of capital, its duration, the party that can still stop it, and the stage each company has reached matter just as much.
| Credit layer | What was published on April 24 | Key number | What it proves | What is still missing |
|---|---|---|---|---|
| Public bond market | Institutional tender for two series expansions | Demand of about NIS 1.50 billion par value, planned acceptance of about NIS 949 million par value | Significant institutional demand for a large real-estate issuer's debt | Rating approval for the larger amount, shelf offering report, TASE approval, and completion of the offering |
| Bank facility | Extension of a binding bank facility | NIS 110 million through April 30, 2027 | The bank continues to fund check-discounting activity | Final credit cost, actual utilization, and fit with longer-duration portfolio needs |
| International rating | Stable BBB rating for the parent company | Two notches below the A- rating of the operating insurer | Holding-company cash quality is receiving external validation | Preserving capital buffers, continued subsidiary dividends, and stability in insurance and asset-management businesses |
The three filings are therefore not just another broad sign that the debt market is available to issuers. Each case is underwriting something different: income-producing real estate with traded debt, a non-bank lender that needs bank lines, and a financial holding company supported by dividends and regulatory capital buffers.
Mega Or has large demand, but the issuance still needs approvals
MEGA OR provides the strongest quantitative signal. In the Series 9 institutional tender, investors submitted orders for about NIS 456 million par value, with total value of about NIS 516 million. The company intends to accept about NIS 198 million par value of early commitments, at NIS 1,131 per NIS 1,000 par value.
Series 11 was larger: orders for about NIS 1.046 billion par value, total value of about NIS 1.127 billion, and intended early commitments of about NIS 751 million par value at NIS 1,076 per NIS 1,000 par value. Together, MEGA OR received demand of about NIS 1.50 billion par value and plans to accept about NIS 949 million par value.
Still, that is not cash in the account yet. Completion depends on approvals, including rating-company approval for the enlarged amount, TASE approval to publish a shelf offering report and list the bonds, and internal corporate approvals. The prior rating notice referred to Series 9 and 11 issuance of up to NIS 500 million par value, while planned accepted commitments are far above that level. Rating approval is therefore not a technical item. It is one of the conditions separating institutional demand from completed funding.
Opal Balance renews bank support, not maturity matching
OPAL BALANCE shows a different credit layer. Its subsidiaries signed an updated framework agreement with Bank B for a NIS 110 million facility. The credit is short term, up to 12 months, with a final utilization date of April 30, 2027. It is designated only for financing against checks, and the interest rate will be agreed in writing before drawdown. If no specific rate is agreed, the bank's customary rate for similar credit at that time will apply.
That is a useful funding source for check discounting, but it does not fully answer the question of source matching for a longer portfolio. At the end of 2025, OPAL BALANCE had a net credit portfolio of about NIS 569 million, and a net mortgage portfolio of about NIS 94 million. Within the mortgage book, 91% of loans were for one to four years, with an average duration of about 3.2 years.
That gap explains why the bank extension is positive but limited. OPAL BALANCE presented bank facilities of about NIS 707 million, of which more than NIS 400 million was unused, so broader bank access exists. Even so, the company describes short-term dependence on two central banks. If one reduces or ends the relationship, management believes alternative financiers can be found, but acknowledges that business and results may be materially affected during the interim period. The bank is renewing confidence, while reminding investors who controls the key.
Phoenix's BBB rating tests parent-company cash quality
For PHOENIX, the filing is neither an issuance nor a credit line. S&P Global assigned the parent company a stable BBB international rating. The agency treats PHOENIX as a NOHC, a non-operating holding company, of a leading Israeli financial-services group. The rating is two notches below the A- rating of the operating insurer, while Israeli insurance NOHCs typically carry a three-notch gap.
The narrower gap reflects the quality of non-insurance cash sources. In 2025, PHOENIX received about NIS 1.8 billion of dividends from group entities, with almost 30% coming from non-insurance operations. S&P expects that share to rise to about 40% in 2026-2028. That reduces dependence on the insurance company's distributions and strengthens holding-company coverage of interest, overhead, and near-term obligations.
The rating also rests on excess capital. The insurance company's solvency ratio stood at 179% at the end of September, above the 150%-170% operating target range and above the group's internal dividend thresholds. On April 23, S&P Maalot reaffirmed a local ilAA rating with a stable outlook. Together, the two filings say that the company is not merely able to access funding. Its dividend structure and parent-level liquidity can support a standalone rating.
The next test is terms, not size
The next read for all three companies will depend less on credit availability and more on attached conditions. For MEGA OR, the question is whether demand becomes a completed offering, and on what final terms, after rating and TASE approvals. For OPAL BALANCE, the question is the facility's cost, actual drawdown, and whether short sources are sufficient for a portfolio where part of the book is longer. For PHOENIX, the question is whether non-insurance dividends keep growing without weakening capital buffers or distribution capacity.
There is also a clear counter-thesis. The April 24 filings may not point to broad credit easing, but to better lender selection. A large real-estate issuer receives demand, subject to rating conditions. A non-bank lender receives a bank, through a defined and short facility. An insurance group receives an international rating after already demonstrating a diversified dividend stream. If that is the right read, the debt market is not becoming easy. It is becoming more selective.
The three filings improve the picture of credit access, but not with the same quality or risk. PHOENIX sits at the higher-quality end of the scale, MEGA OR is testing bond-market depth, and OPAL BALANCE receives an important but short bank extension. The next filings that will move the picture are the actual bond approval and terms, the bank facility's cost, and the pace of dividends reaching the holding company.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.